Patient explainer · Learn

Longevity Medications and Supplements

The Potential of Rapamycin, Metformin, and Other Supplements in Longevity Medicine: Emerging Research and Clinical Implications

By Jason Glowney, MD.

This is a detailed subject, and what it means for your situation depends on your history and your imaging. Dr. Glowney is glad to work through it with you.

Schedule a call → 720-550-6175

Rapamycin and metformin.

Rapamycin and metformin are two pharmacological agents that are widely studied in longevity medicine because they can modulate key biological pathways associated with aging and chronic disease. Rapamycin, a macrolide compound initially discovered as an antifungal agent, has been found to have immunosuppressive and anti-proliferative properties, leading to its approval for preventing organ transplant rejection. Its potential role in longevity medicine arises from its ability to inhibit the mechanistic target of rapamycin (mTOR) pathway, a central regulator of cellular growth, metabolism, and autophagy. (Li et al., 2014) Rapamycin selectively inhibits mTORC1, reducing cellular growth signals and promoting autophagy, clearing damaged organelles and proteins. (Li et al., 2014) In animal studies, rapamycin has consistently extended lifespan across multiple species, including yeast, worms, flies, and mice. (Li et al., 2014) In these animal studies, it also improved metabolic health, reduced inflammation, and protected against age-related diseases such as cancer, neurodegeneration, and cardiovascular disorders. (Li et al., 2014) However, concerns about immunosuppression and side effects, such as hyperlipidemia and insulin resistance, have spurred interest in optimizing dosing regimens, including intermittent use to balance benefits and risks. (Lamming et al., 2012)

Metformin, a widely used drug for type 2 diabetes, has emerged as another promising candidate for longevity medicine. It works primarily by activating AMP-activated protein kinase, a cellular energy sensor that enhances insulin sensitivity, promotes mitochondrial health, and indirectly inhibits mTOR signaling. (Soukas et al., 2019) Recent studies have indicated that eliminating damaged mitochondria via mitophagy may be one of the mechanisms responsible for the beneficial effects of rapamycin. (Chen et al., 2020) The antidiabetic effects of metformin and its anti-aging properties in model organisms have led researchers to study it as a possible anti-aging therapy. (Soukas et al., 2019) However, uncertainties exist in metformin's mechanisms and side effects that may prevent its widespread use in aging in otherwise healthy individuals. (Soukas et al., 2019) Neither drug is FDA-approved to slow aging or extend lifespan, so prescribing either one for that purpose is off-label.

What the two drugs share, and the open questions.

Rapamycin and metformin have shown promising results in their potential to modulate key biological pathways associated with aging and chronic disease. Further research is needed to optimize their use and address the concerns regarding side effects and long-term safety.

Rapamycin and metformin have distinct mechanisms of action, but both target cellular pathways implicated in the aging process. Rapamycin inhibits the mTOR pathway, reducing cellular growth signals and promoting autophagy, while metformin activates AMPK, enhancing insulin sensitivity and inhibiting mTOR. (Li et al., 2014)(Soukas et al., 2019) Animal studies have consistently shown that rapamycin can extend lifespan across multiple species, and it has been found to improve metabolic health, reduce inflammation, and protect against age-related diseases. (Li et al., 2014) Metformin, on the other hand, has also exhibited anti-aging properties in model organisms, potentially through its ability to promote mitochondrial health and mitophagy. (De Haes et al., 2014) (Chen et al., 2020)

While these pharmacological agents hold promise in longevity medicine, concerns and uncertainties must be addressed. Rapamycin's immunosuppressive effects and potential side effects, such as hyperlipidemia and insulin resistance, have led to the exploration of optimized dosing regimens, including intermittent use. (Lamming et al., 2012) Similarly, the widespread use of metformin as an anti-aging therapy in otherwise healthy individuals is limited by the incomplete understanding of its mechanisms of action and potential side effects. (Soukas et al., 2019)

Further research is necessary to elucidate the precise mechanisms by which rapamycin and metformin exert their anti-aging effects and develop strategies to mitigate their potential drawbacks. By continuing to investigate these pharmacological agents, researchers may develop more effective and safer interventions to promote healthy aging and delay the onset of age-related diseases.

Mitochondria and aging.

One key area of interest in studying rapamycin and metformin is their potential to modulate mitochondrial function and dynamics. Recent studies have indicated that rapamycin's beneficial effects may be mediated, at least in part, by its ability to enhance mitophagy and the selective degradation of damaged mitochondria. (Chen et al., 2020) Mitochondrial dysfunction is a hallmark of aging and a contributing factor to the development of various age-related diseases. Rapamycin may help maintain mitochondrial homeostasis and contribute to its anti-aging effects by promoting the clearance of dysfunctional mitochondria.

Similarly, metformin has been shown to activate AMPK, which can stimulate mitochondrial biogenesis and enhance mitochondrial function. (De Haes et al., 2014) Through this mitohormetic pathway, metformin may elicit a beneficial response that counteracts the detrimental effects of aging on mitochondria.

As the understanding of the complex interplay between these pharmacological agents and mitochondrial biology continues to evolve, researchers may uncover novel strategies to use these drugs to promote healthy aging and mitigate the burden of age-related diseases.

Supplements under study.

Resveratrol.

In addition to well-studied interventions like rapamycin and metformin, other supplements are being investigated for their potential longevity benefits. One such compound is resveratrol, a polyphenol found in red wine that activates sirtuins, particularly SIRT1, which are involved in DNA repair, metabolic regulation, and mitochondrial function (Liu, 2022). Though promising in preclinical studies, human trials have yielded mixed results, partly due to poor bioavailability (Alarcón‐de‐la‐Lastra & Villegas, 2005).

NAD+ precursors.

Another focus of longevity research is on nicotinamide riboside and nicotinamide mononucleotide, which aim to replenish declining NAD+ levels observed with aging (Rajman et al., 2018; Martens et al., 2018). NAD+ is essential for mitochondrial function, DNA repair, and cellular energy metabolism. Early human studies of these NAD+ precursors are mixed: one small trial found lower levels of inflammatory markers in older men (Elhassan et al., 2019), and another found better insulin sensitivity in women with prediabetes (Yoshino et al., 2021), while a third found no change in insulin sensitivity in obese men (Dollerup et al., 2018).

Quercetin.

Quercetin, a flavonoid with anti-inflammatory and antioxidant properties, is also being studied for its potential to enhance cellular resilience and combat senescence. Combined with the chemotherapeutic agent dasatinib, quercetin acts as a senolytic, selectively clearing senescent cells that contribute to aging and chronic inflammation (Zhu et al., 2015).

Spermidine.

Spermidine, a naturally occurring polyamine found in foods like wheat germ, promotes autophagy and has shown promise in preclinical models for extending lifespan and improving cardiovascular health (Eisenberg et al., 2016). Early human studies suggest it may also improve memory and reduce inflammation (Wirth et al., 2018; Schwarz et al., 2022).

Omega-3s, curcumin, and CoQ10.

Other notable supplements with potential longevity benefits include omega-3 fatty acids, which support cardiovascular and brain health through anti-inflammatory mechanisms, and curcumin, the active component of turmeric, known for its ability to modulate inflammation and oxidative stress. Coenzyme Q10 and its reduced form, ubiquinol, are key components of the mitochondrial electron transport chain and have been shown to improve mitochondrial function, particularly in conditions of age-related decline (Hernández-Camacho et al., 2018).

Where the research stands.

The emerging research on these and other longevity-promoting supplements shows how complex the aging process is. As we unravel the underlying mechanisms, these compounds may offer promising strategies for maintaining health and delaying the onset of age-associated diseases.

While the supplements discussed have shown potential in preclinical and early human studies, it is important to note that the field of longevity research is still nascent, and more robust clinical trials are needed to establish the safety and efficacy of these interventions.

Pursuing longevity through dietary supplements and natural compounds is a rapidly evolving field of research. Compounds like resveratrol, NAD+ precursors, quercetin, spermidine, and others have demonstrated promising results in preclinical studies and early human trials, suggesting they may play a role in extending healthy lifespan and delaying age-related diseases.

As the global population ages, this research has significant implications for public health and the potential to improve the quality of life for older adults. However, more comprehensive clinical studies are needed to fully understand these interventions' long-term safety and efficacy.

While these supplements show promise, they are best approached with cautious optimism. A balanced, evidence-based approach, combined with ongoing research, will be essential in determining the true potential of these longevity-promoting compounds.

The future of longevity research lies in the continued exploration of these and other natural compounds and the development of novel interventions that target the underlying hallmarks of aging.

References

Sources cited.

Chen, G., Kroemer, G., & Kepp, O. (2020). Mitophagy: An Emerging Role in Aging and Age-Associated Diseases [Review of Mitophagy: An Emerging Role in Aging and Age-Associated Diseases]. Frontiers in Cell and Developmental Biology, 8. Frontiers Media. https://doi.org/10.3389/fcell.2020.00200
De Haes, W., Frooninckx, L., Van Assche, R., Smolders, A., Depuydt, G., Billen, J., Braeckman, B. P., Schoofs, L., & Temmerman, L. (2014). Metformin promotes lifespan through mitohormesis via the peroxiredoxin PRDX-2. In W. De Haes, L. Frooninckx, R. Van Assche, A. Smolders, G. Depuydt, J. Billen, B. P. Braeckman, L. Schoofs, & L. Temmerman, Proceedings of the National Academy of Sciences (Vol. 111, Issue 24). National Academy of Sciences. https://doi.org/10.1073/pnas.1321776111
Lamming, D. W., Ye, L., Katajisto, P., Goncalves, M. D., Saitoh, M., Stevens, D. M., Davis, J. G., Salmon, A. B., Richardson, A., Ahima, R. S., Guertin, D. A., Sabatini, D. M., & Baur, J. A. (2012). Rapamycin-Induced Insulin Resistance Is Mediated by mTORC2 Loss and Uncoupled from Longevity. In D. W. Lamming, L. Ye, P. Katajisto, M. D. Goncalves, M. Saitoh, D. M. Stevens, J. G. Davis, A. B. Salmon, A. Richardson, R. S. Ahima, D. A. Guertin, D. M. Sabatini, & J. A. Baur, Science (Vol. 335, Issue 6076, p. 1638). American Association for the Advancement of Science. https://doi.org/10.1126/science.1215135
Li, J., Kim, S. G., & Blenis, J. (2014). Rapamycin: One Drug, Many Effects [Review of Rapamycin: One Drug, Many Effects]. Cell Metabolism, 19(3), 373. Cell Press. https://doi.org/10.1016/j.cmet.2014.01.001
Soukas, A. A., Hao, H., & Wu, L. (2019). Metformin as Anti-Aging Therapy: Is It for Everyone? [Review of Metformin as Anti-Aging Therapy: Is It for Everyone?]. Trends in Endocrinology and Metabolism, 30(10), 745. Elsevier BV. https://doi.org/10.1016/j.tem.2019.07.015
Alarcón‐de‐la‐Lastra, C., & Villegas, I. (2005). Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications [Review of Resveratrol as an anti-inflammatory and anti-aging agent: Mechanisms and clinical implications]. Molecular Nutrition & Food Research, 49(5), 405. Wiley. https://doi.org/10.1002/mnfr.200500022
Dollerup, O. L., Christensen, B., Svart, M., Schmidt, M. S., Sulek, K., Ringgaard, S., Stødkilde-Jørgensen, H., Møller, N., Brenner, C., Treebak, J. T., & Jessen, N. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: Safety, insulin-sensitivity, and lipid-mobilizing effects. The American Journal of Clinical Nutrition, 108(2), 343–353. https://doi.org/10.1093/ajcn/nqy132
Eisenberg, T., Abdellatif, M., Schroeder, S., Primessnig, U., Stekovic, S., Pendl, T., Harger, A., Schipke, J., Zimmermann, A., Schmidt, A., Tong, M., Ruckenstuhl, C., Dammbrueck, C., Gross, A. S., Herbst, V., Magnes, C., Trausinger, G., Narath, S., Meinitzer, A., … Madeo, F. (2016). Cardioprotection and lifespan extension by the natural polyamine spermidine. Nature Medicine, 22(12), 1428–1438. https://doi.org/10.1038/nm.4222
Elhassan, Y. S., Kluckova, K., Fletcher, R. S., Schmidt, M. S., Garten, A., Doig, C. L., Cartwright, D. M., Oakey, L., Burley, C. V., Jenkinson, N., Wilson, M., Lucas, S. J. E., Akerman, I., Seabright, A., Lai, Y.-C., Tennant, D. A., Nightingale, P., Wallis, G. A., Manolopoulos, K. N., … Lavery, G. G. (2019). Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 28(7), 1717–1728.e6. https://doi.org/10.1016/j.celrep.2019.07.043
Hernández-Camacho, J. D., Bernier, M., López-Lluch, G., & Navas, P. (2018). Coenzyme Q10 supplementation in aging and disease. Frontiers in Physiology, 9, 44. https://doi.org/10.3389/fphys.2018.00044
Liu, J. (2022). Antiaging agents: safe interventions to slow aging and healthy life span extension [Review of Antiaging agents: safe interventions to slow aging and healthy life span extension]. Natural Products and Bioprospecting, 12(1). Springer Science+Business Media. https://doi.org/10.1007/s13659-022-00339-y
Martens, C. R., Denman, B. A., Mazzo, M. R., Armstrong, M. L., Reisdorph, N., McQueen, M. B., Chonchol, M., & Seals, D. R. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9(1), 1286. https://doi.org/10.1038/s41467-018-03421-7
Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic potential of NAD-boosting molecules: The in vivo evidence. Cell Metabolism, 27(3), 529–547. https://doi.org/10.1016/j.cmet.2018.02.011
Schwarz, C., Benson, G. S., Horn, N., Wurdack, K., Grittner, U., Schilling, R., Märschenz, S., Köbe, T., Hofer, S. J., Magnes, C., Stekovic, S., Eisenberg, T., Sigrist, S. J., Schmitz, D., Wirth, M., Madeo, F., & Flöel, A. (2022). Effects of spermidine supplementation on cognition and biomarkers in older adults with subjective cognitive decline: A randomized clinical trial. JAMA Network Open, 5(5), e2213875. https://doi.org/10.1001/jamanetworkopen.2022.13875
Wirth, M., Benson, G., Schwarz, C., Köbe, T., Grittner, U., Schmitz, D., Sigrist, S. J., Bohlken, J., Stekovic, S., Madeo, F., & Flöel, A. (2018). The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. Cortex, 109, 181–188. https://doi.org/10.1016/j.cortex.2018.09.014
Yoshino, M., Yoshino, J., Kayser, B. D., Patti, G. J., Franczyk, M. P., Mills, K. F., Sindelar, M., Pietka, T., Patterson, B. W., Imai, S.-I., & Klein, S. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. https://doi.org/10.1126/science.abe9985
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., O'Hara, S. P., LaRusso, N. F., Miller, J. D., Roos, C. M., Verzosa, G. C., LeBrasseur, N. K., Wren, J. D., Farr, J. N., Khosla, S., … Kirkland, J. L. (2015). The Achilles' heel of senescent cells: From transcriptome to senolytic drugs. Aging Cell, 14(4), 644–658. https://doi.org/10.1111/acel.12344

Related patient explainers